Acasă › Cancer metastatic › North Carolina › Durham
Studii clinice pentru Cancer metastatic în Durham, NC
33 studii pentru Cancer metastatic caută participanți în și în jurul orașului Durham (în aproximativ 50 km). Deschideți un studiu pentru a vedea criteriile de eligibilitate și cum să contactați echipa de cercetare.
Text oficial al studiului (în engleză)
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
În curs de recrutareFaza 1/2
- Avenzo Therapeutics Recruiting Site, Chapel Hill · La 10 mi distanță
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
În curs de recrutareFaza 2
- Duke University Medical Center, Durham
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
În curs de recrutareFaza 1/2
- Duke University, Durham
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
În curs de recrutareFaza 2/3
- Duke University Medical Center, Durham
- University of North Carolina at Chapel Hill, Chapel Hill · La 10 mi distanță
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
În curs de recrutareFaza 3
- Duke Cancer Center - Investigational Chemotherapy Service, Durham
- Duke Cancer Center, Durham
- Duke University Hospital - Vascular Interventional Radiology, Durham
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
În curs de recrutareFaza 2
- Duke Cancer Institute, Durham
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
În curs de recrutareFaza 2/3
- UNC Hospitals, The University of North Carolina at Chapel Hill, Chapel Hill · La 10 mi distanță
- University of North Carolina Hospitals at Hillsborough, Hillsborough · La 13 mi distanță
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
În curs de recrutareFaza 3
- Duke Cancer Institute, Durham
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
În curs de recrutareFaza 3
- University of North Carolina Medical Center, Chapel Hill · La 10 mi distanță
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
În curs de recrutareFaza 3
- Duke Cancer Institute, Durham
- University of North Carolina Medical Center, Chapel Hill · La 10 mi distanță
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
În curs de recrutareFaza 1
- University of North Carolina (UNC) - Chapel Hill, Chapel Hill · La 10 mi distanță
FOG-001 in Locally Advanced or Metastatic Solid Tumors
În curs de recrutareFaza 1/2
- Duke University, Durham
PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
În curs de recrutare
- Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill · La 10 mi distanță
A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)
În curs de recrutareFaza 1
- Duke Cancer Center, Durham
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
În curs de recrutareFaza 1
- Research Site, Durham
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
În curs de recrutareFaza 1
- Research Site, Durham
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
În curs de recrutareFaza 1
- Duke Cancer Center, Durham
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
În curs de recrutareFaza 1/2
- Duke University Medical Center, Durham
UNC Childhood, Adolescent, and Young Adult Cancer Cohort
În curs de recrutareStudiu observațional
- University of North Carolina at Chapel Hill, Chapel Hill · La 10 mi distanță
UNC Metastatic Cancer Radiation Therapy Registry
În curs de recrutareStudiu observațional
- Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, Chapel Hill · La 10 mi distanță
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
În curs de recrutareFaza 1/2
- University of North Carolina at Chapel Hill, Chapel Hill · La 10 mi distanță
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
În curs de recrutareFaza 2/3
- Durham VA Medical Center, Durham, NC, Durham
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
În curs de recrutareFaza 2/3
- Duke University Medical Center, Durham
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
În curs de recrutareFaza 1/2
- Duke Cancer Center/ DUMC, Durham
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
În curs de recrutareFaza 1
- Duke Cancer Institute, Durham
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
În curs de recrutareFaza 3
- Duke University, Durham
Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry
În curs de recrutareStudiu observațional
- Durham Veterans Administration Health Care System (DVAHCS), Durham
- Duke University Medical Center, Durham
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
În curs de recrutareFaza 1
- Duke Cancer Center, Durham
ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer
În curs de recrutareFaza 1
- Lineberger Comprehensive Cancer Center, Chapel Hill · La 10 mi distanță
JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors
În curs de recrutareFaza 1
- Duke University Medical Center - Duke Cancer Institute, Durham
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
În curs de recrutareStudiu observațional
- Massive Bio SYNERGY-AI site, Chapel Hill · La 10 mi distanță
A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)
În curs de recrutareFaza 3
- Duke University - Trent Center, Durham
A Study of NX-1607 in Adults With Advanced Malignancies
În curs de recrutareFaza 1
- University of North Carolina, Chapel Hill · La 10 mi distanță
Studii pentru Cancer metastatic în alte orașe
- Houston, TX104 studii
- New York City, NY93 studii
- Nashville, TN70 studii
- Boston, MA63 studii
- Los Angeles, CA57 studii
- St. Louis, MO54 studii
- Arlington, VA53 studii
- Philadelphia, PA46 studii
- Chicago, IL45 studii
- San Antonio, TX44 studii
- Washington, DC43 studii
- Dallas, TX42 studii
Alte studii în Durham
- Cancer de sân64 studii
- Cancer (toate tipurile)58 studii
- Cancer pulmonar cu celule non-pătrate39 studii
- Mielom multiplu37 studii
- Leucemie mieloasă acută33 studii
- Cancer de prostată32 studii
- Cancer pulmonar32 studii
- Cancer colorectal28 studii
- Cancer ovarian27 studii
- Leucemie limfatică cronică27 studii
- Insuficiență cardiacă26 studii
- Cancer pancreatic24 studii
Sursă: ClinicalTrials.gov, date preluate la 6 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.